Truist Financial Corp Acquires 3,883 Shares of Ultragenyx Pharmaceutical Inc. (NASDAQ:RARE)

Truist Financial Corp boosted its holdings in Ultragenyx Pharmaceutical Inc. (NASDAQ:RAREGet Rating) by 50.8% during the 3rd quarter, Holdings Channel.com reports. The fund owned 11,522 shares of the biopharmaceutical company’s stock after purchasing an additional 3,883 shares during the quarter. Truist Financial Corp’s holdings in Ultragenyx Pharmaceutical were worth $477,000 as of its most recent SEC filing.

Several other large investors have also added to or reduced their stakes in the business. State Street Corp lifted its position in shares of Ultragenyx Pharmaceutical by 26.1% during the 2nd quarter. State Street Corp now owns 2,457,308 shares of the biopharmaceutical company’s stock worth $146,603,000 after buying an additional 508,624 shares in the last quarter. Wellington Management Group LLP lifted its position in shares of Ultragenyx Pharmaceutical by 17.1% during the 1st quarter. Wellington Management Group LLP now owns 3,370,245 shares of the biopharmaceutical company’s stock worth $244,747,000 after buying an additional 492,842 shares in the last quarter. Emerald Advisers LLC lifted its position in shares of Ultragenyx Pharmaceutical by 72.5% during the 3rd quarter. Emerald Advisers LLC now owns 347,081 shares of the biopharmaceutical company’s stock worth $14,373,000 after buying an additional 145,864 shares in the last quarter. Dimensional Fund Advisors LP lifted its position in shares of Ultragenyx Pharmaceutical by 44.1% during the 1st quarter. Dimensional Fund Advisors LP now owns 463,996 shares of the biopharmaceutical company’s stock worth $33,693,000 after buying an additional 141,945 shares in the last quarter. Finally, Deutsche Bank AG lifted its position in shares of Ultragenyx Pharmaceutical by 33.4% during the 2nd quarter. Deutsche Bank AG now owns 487,708 shares of the biopharmaceutical company’s stock worth $29,096,000 after buying an additional 122,180 shares in the last quarter. Institutional investors own 93.17% of the company’s stock.

Insider Activity

In other news, CAO Theodore Alan Huizenga sold 2,031 shares of the business’s stock in a transaction on Wednesday, December 21st. The shares were sold at an average price of $43.96, for a total transaction of $89,282.76. Following the completion of the transaction, the chief accounting officer now directly owns 16,197 shares in the company, valued at approximately $712,020.12. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through the SEC website. Company insiders own 6.70% of the company’s stock.

Ultragenyx Pharmaceutical Price Performance

RARE opened at $42.81 on Tuesday. The company has a fifty day moving average price of $41.33 and a 200-day moving average price of $44.65. The firm has a market capitalization of $3.00 billion, a P/E ratio of -4.40 and a beta of 1.01. Ultragenyx Pharmaceutical Inc. has a one year low of $33.36 and a one year high of $85.53.

Ultragenyx Pharmaceutical (NASDAQ:RAREGet Rating) last released its quarterly earnings results on Wednesday, November 2nd. The biopharmaceutical company reported ($2.43) EPS for the quarter, missing analysts’ consensus estimates of ($2.29) by ($0.14). The firm had revenue of $90.70 million for the quarter, compared to analysts’ expectations of $98.76 million. Ultragenyx Pharmaceutical had a negative net margin of 197.47% and a negative return on equity of 84.14%. On average, analysts expect that Ultragenyx Pharmaceutical Inc. will post -8.82 earnings per share for the current year.

Analyst Upgrades and Downgrades

Several equities analysts have commented on the stock. Cowen dropped their target price on shares of Ultragenyx Pharmaceutical from $86.00 to $65.00 in a research report on Thursday, November 3rd. Wedbush reaffirmed a “neutral” rating on shares of Ultragenyx Pharmaceutical in a report on Thursday, October 13th. Credit Suisse Group lowered their price target on shares of Ultragenyx Pharmaceutical from $105.00 to $96.00 and set an “outperform” rating on the stock in a report on Thursday, November 3rd. The Goldman Sachs Group lowered their price target on shares of Ultragenyx Pharmaceutical from $74.00 to $55.00 and set a “neutral” rating on the stock in a report on Friday, November 4th. Finally, SVB Leerink lowered their price target on shares of Ultragenyx Pharmaceutical from $115.00 to $108.00 and set an “outperform” rating on the stock in a report on Thursday, November 3rd. One analyst has rated the stock with a sell rating, two have assigned a hold rating and ten have issued a buy rating to the company’s stock. Based on data from MarketBeat.com, Ultragenyx Pharmaceutical has an average rating of “Moderate Buy” and an average price target of $92.00.

About Ultragenyx Pharmaceutical

(Get Rating)

Ultragenyx Pharmaceutical, Inc is a biopharmaceutical company, engaged in the identification, acquisition, development and commercialization of novel products for the treatment of serious rare and ultra-rare genetic diseases. Its products include Mepsevii and Crysvita. Mepsevii is an intravenous enzyme replacement therapy, which is used for the treatment of Mucopolysaccharidosis VII.

Further Reading

Want to see what other hedge funds are holding RARE? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Ultragenyx Pharmaceutical Inc. (NASDAQ:RAREGet Rating).

Institutional Ownership by Quarter for Ultragenyx Pharmaceutical (NASDAQ:RARE)

Receive News & Ratings for Ultragenyx Pharmaceutical Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Ultragenyx Pharmaceutical and related companies with MarketBeat.com's FREE daily email newsletter.